Taken together, these data support that therapeutic intervention with a GalNAc-conjugated siRNA targeting Mtarc1 in a highly lipogenic diet model of MASH can significantly reduce liver fat accumulation and hepatocyte ballooning. This evidence concerns the gene MTARC1 and metabolic dysfunction-associated steatohepatitis.